Purdue Pharma made millions by selling OxyContin and it's now set to profit off the cure for an addiction they manufactured.
The treatment is a new formulation of buprenorphine, which has been shown to help people with opioid addiction.
The patent on the new buprenorphin was issued in January.
Purdue Pharma is the subject of many lawsuits for allegedly fueling the opioid epidemic.
Critics said it was "sick" that Dr Sackler could benefit financially from a crisis that contributed to the deaths of more than 42,000 people in 2016, in part driven by addiction to OxyContin.
Purdue has denied the allegations in the lawsuits, which also target a range of other opioid painkiller manufacturers and distributors.
The patent relates to a drug which is a reformulation of buprenorphine, a milder opioid that can boring the symptoms of withdrawal from the stronger narcotic. It is already approved by the Food and Drug Administration in tablet and film form, but the patent describes a wafer that could dissolve even faster than existing forms when put under the tongue.
The patent says that the faster the treatment dissolves, the less risk there is for diversion.
Sackler is the past president of Purdue; his father was one of three brothers who founded the company.
The Sackler family owns Purdue Pharma, the first RX company to develop the highly addicting drug OxyContin. Massachusetts Attorney General Maura Healey directly names several members of the Sackler family as defendants.
The CDC states that both illegal opioids and prescription opioids, which are commonly used to treat pain, have been associated with addiction, overdoses and death. Opioids remain a necessary tool to treat severe pain from surgery, cancer, and other serious conditions, but they must be used judiciously, and alternative therapies must be made available - particularly in lower-income rural areas where people are at higher risk.
A Purdue spokesman declined to answer questions about the patent, calling the FT report "a story built on speculation".
The grant is being given to Pittsburgh-based Harm Reduction Therapeutics, which is trying to develop a low-priced nasal spray with the opioid overdose antidote naloxone.